Comprehensive transcriptome and scRNA‐seq analyses uncover the expression and underlying mechanism of SYNJ2 in papillary thyroid carcinoma

Autor: Yuan‐Ping Yang, Zhi‐Guang Huang, Jia‐Yuan Luo, Juan He, Lin Shi, Gang Chen, Si‐Yuan Chen, Yu‐Wen Deng, Yi‐Jia Yang, Yi‐Jun Tang, Yu‐Yan Pang
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: IET Systems Biology, Vol 18, Iss 5, Pp 183-198 (2024)
Druh dokumentu: article
ISSN: 1751-8857
1751-8849
DOI: 10.1049/syb2.12099
Popis: Abstract Synaptojanin 2 (SYNJ2) has crucial role in various tumors, but its role in papillary thyroid carcinoma (PTC) remains unexplored. This study first detected SYNJ2 protein expression in PTC using immunohistochemistry method and further assessed SYNJ2 mRNA expression through mRNA chip and RNA sequencing data and its association with clinical characteristics. Additionally, KEGG, GSVA, and GSEA analyses were conducted to investigate potential biological functions, while single‐cell RNA sequencing data were used to explore SYNJ2's underlying mechanisms in PTC. Meanwhile, immune infiltration status in different SYNJ2 expression groups were analyzed. Besides, we investigated the immune checkpoint gene expression and implemented drug sensitivity analysis. Results indicated that SYNJ2 is highly expressed in PTC (SMD = 0.66 [95% CI: 0.17–1.15]) and could distinguish between PTC and non‐PTC tissues (AUC = 0.74 [0.70–0.78]). Furthermore, the study identified 134 intersecting genes of DEGs and CEGs, mainly enriched in the angiogenesis and epithelial‐mesenchymal transition (EMT) pathways. Subsequent analysis showed the above pathways were activated in PTC epithelial cells. PTC patients with high SYNJ2 expression showed higher sensitivity to the six common drugs. Summarily, SYNJ2 may promote PTC progression through angiogenesis and EMT pathways. High SYNJ2 expression is associated with better response to immunotherapy and chemotherapy.
Databáze: Directory of Open Access Journals
Externí odkaz: